Five-year survival of patients with hilar cholangiocarcinoma: a single-center retrospective study.

IF 1.6 4区医学 Q3 SURGERY

Annals of Surgical Treatment and Research Pub Date : 2025-08-01 Epub Date: 2025-07-30 DOI:10.4174/astr.2025.109.2.71

HyeJeong Jeong, Hee Joon Kim, Soo Yeun Lim, Hyun Jeong Jeon, So Jeong Yoon, Hongbeom Kim, In Woong Han, Jin Seok Heo, Sang Hyun Shin

{"title":"Five-year survival of patients with hilar cholangiocarcinoma: a single-center retrospective study.","authors":"HyeJeong Jeong, Hee Joon Kim, Soo Yeun Lim, Hyun Jeong Jeon, So Jeong Yoon, Hongbeom Kim, In Woong Han, Jin Seok Heo, Sang Hyun Shin","doi":"10.4174/astr.2025.109.2.71","DOIUrl":null,"url":null,"abstract":"Purpose: Hilar cholangiocarcinoma is known for its poor prognosis due to late diagnosis. To achieve long-term survival, curative resection often is necessary. However, after surgical resection, the 5-year survival rates vary from 14% to 48%. The aim of this study is to evaluate the prognostic factors for long-term survival in hilar cholangiocarcinoma.Methods: Patients who underwent curative resection for hilar cholangiocarcinoma at Samsung Medical Center from January 2000 to December 2020 were included. Demographics, surgical and oncological outcomes, short-term complications, recurrence, pathologic results, and survival were analyzed. Prognostic factors were analyzed with Cox proportional hazards models.Results: A total of 449 patients diagnosed with hilar cholangiocarcinoma who underwent intent-to-treat resection at Samsung Medical Center from 2000 to 2020 were included in this study. The median disease-free survival was 19 months, and the median survival was 40 months. One-, 3-, and 5-year survival rates were 82.8%, 53.7%, and 35.8%, respectively.Conclusion: The 5-year survival rate of patients with hilar cholangiocarcinoma was 35.8% at Samsung Medical Center. Median survival was 40 months. N2 stage and tumor biology were factors affecting 5-year survival.","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"71-80"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329132/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Treatment and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4174/astr.2025.109.2.71","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Hilar cholangiocarcinoma is known for its poor prognosis due to late diagnosis. To achieve long-term survival, curative resection often is necessary. However, after surgical resection, the 5-year survival rates vary from 14% to 48%. The aim of this study is to evaluate the prognostic factors for long-term survival in hilar cholangiocarcinoma.

Methods: Patients who underwent curative resection for hilar cholangiocarcinoma at Samsung Medical Center from January 2000 to December 2020 were included. Demographics, surgical and oncological outcomes, short-term complications, recurrence, pathologic results, and survival were analyzed. Prognostic factors were analyzed with Cox proportional hazards models.

Results: A total of 449 patients diagnosed with hilar cholangiocarcinoma who underwent intent-to-treat resection at Samsung Medical Center from 2000 to 2020 were included in this study. The median disease-free survival was 19 months, and the median survival was 40 months. One-, 3-, and 5-year survival rates were 82.8%, 53.7%, and 35.8%, respectively.

Conclusion: The 5-year survival rate of patients with hilar cholangiocarcinoma was 35.8% at Samsung Medical Center. Median survival was 40 months. N2 stage and tumor biology were factors affecting 5-year survival.

Abstract Image

查看原文本刊更多论文

肝门胆管癌患者的五年生存率：一项单中心回顾性研究。

目的：肝门胆管癌诊断较晚，预后较差。为了达到长期生存，治疗性切除往往是必要的。然而，手术切除后，5年生存率从14%到48%不等。本研究的目的是评估肝门胆管癌患者长期生存的预后因素。方法：选取2000年1月至2020年12月在三星医院行肝门胆管癌根治性手术的患者。分析了人口统计学、手术和肿瘤预后、短期并发症、复发、病理结果和生存率。采用Cox比例风险模型分析预后因素。结果：从2000年到2020年，共有449名确诊为肝门胆管癌的患者在三星首尔医院接受了有意治疗性切除术。中位无病生存期为19个月，中位生存期为40个月。1年、3年和5年生存率分别为82.8%、53.7%和35.8%。结论：三星医院肝门胆管癌患者5年生存率为35.8%。中位生存期为40个月。N2分期和肿瘤生物学是影响5年生存率的因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Surgical Treatment and Research SURGERY-

CiteScore

2.30

自引率

7.10%

发文量

期刊介绍： Manuscripts to the Annals of Surgical Treatment and Research (Ann Surg Treat Res) should be written in English according to the instructions for authors. If the details are not described below, the style should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publications available at International Committee of Medical Journal Editors (ICMJE) website (http://www.icmje.org).